Skip to content

Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

Department of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Research Center for Neuro-Oncology Interaction , Institute of Basic Medicine and Cancer, Chinese Academy of Sciences

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05468671
Enrollment
34
Registered
2022-07-21
Start date
2021-01-04
Completion date
2022-09-08
Last updated
2022-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchoesophageal Fistula, Endobronchial Metastases, General Anesthetic Drug Adverse Reaction

Brief summary

This study is a prospective, randomized, controlled trial. In this study, 30 patients who underwent endotracheal tumor resection under rigid bronchoscope or stent placement for acquired tracheoesophageal fistula were selected as the subjects. The patients were randomly divided into remazolam general anesthesia group (R group) and propofol general anesthesia control group (P group). Remazolam general anesthesia group (R group): Remazolam 0.4 mg/kg, oxycodone 0.2 mg/kg and rocuronium 0.9 mg/kg were given for anesthesia induction. Propofol general anesthesia control group (P group): Propofol 1.5mg/kg, oxycodone 0.2mg/kg and rocuronium 0.9mg/kg were given for induction of anesthesia. After induction, high-frequency jet ventilation was used in both groups, the respiratory rate was 30-60 times/min, the inspiratory-to-breath ratio was 1:2, and the driving pressure was 0.8-1.0 KPa. Group R was given remazolam 1mg/kg/h and remifentanil 6-8ug/kg/h for maintenance. Group P was given propofol 4-8 mg/kg/h and remifentanil 6-8ug/kg/h for anesthesia maintenance. The dosage of propofol or remazolam was adjusted according to BIS and intraoperative hemodynamic changes. Rocuronium bromide 10 mg was added every half hour. Intraoperative application of vasoactive drugs to maintain mean arterial pressure above 60mmHg to avoid perioperative hypotension. Blood oxygen saturation and end-tidal carbon dioxide were monitored to avoid perioperative hypoxemia and hypercapnia, and warm measures were used to maintain the patient's intraoperative body temperature above 36.0°C. After surgery, group R was treated with sugammadex sodium 2-4 mg/kg to antagonize rocuronium bromide, and 0.5 mg of flumazenil was used to antagonize remazolam by intravenous injection; group P was treated with sugammadex 2-4 mg/kg to antagonize rocuronium.

Interventions

DRUGRemifentanil

Remifentanil is an esterase-metabolized opioid

DRUGoxycodone

Oxycodone is an opiate painkiller.

DRUGRemimazolam

Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.

DRUGPropofol

Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.

DRUGRocuronium

Rocuronium is a non-depolarizing neuromuscular blocker

Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery

DRUGFlumazenil

Flumazenil is used to reverse the effects of a benzodiazepine

Sponsors

Zhejiang Cancer Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing bronchoscopy endotracheal tumor resection or stenting of acquired tracheoesophageal fistula within a limited time * \>18 Years * ASA Ⅱ-Ⅳ

Exclusion criteria

* \<18Years * Refuse to participate * A history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis; * Severe hepatic dysfunction (Child-Pugh class C) * Severe renal dysfunction (requiring dialysis) * Patients with ASA grade Ⅴ and above * Emergency Surgery

Design outcomes

Primary

MeasureTime frameDescription
Recovery time in secondspostoperative, 2 hoursTaking the stop of general anesthesia as the starting point for timing, the time for the patient to correctly complete the three commands of nodding, mouth opening and tongue extension is recorded, with seconds as the timing unit

Secondary

MeasureTime frameDescription
Intraoperative mean arterial blood pressure in mmHgIntraoperative,4hoursFluctuations in intraoperative systolic, diastolic pressures and mean arterial pressure will be recorded
Perioperative Nutrition Status Assessment Scale (PONS) in YES or NOBaseline, 1 yearPONS is a modified version of the malnutrition universal screening tool and determines the presence of nutrition risk based on BMI, recent body weight loss, decrement of dietary intake, and preoperative albumin concentration.
Onset time in secondsInduction of anesthesia,10 minutesThe time from the start of peripheral intravenous injection of general anesthetic to the patient's loss of consciousness. Time is measured in seconds.
Modified Brice Questionnaire in YES or NOpostoperative,24 hoursModified Brice interview over quality assurance techniques in detecting intraoperative awareness.
Intraoperative heart rate in beats per minuteIntraoperative,4hoursFluctuations in intraoperative heart rate will be recorded
The incidence of postoperative vomiting in ratepostoperative,24 hoursThe proportion of cases of postoperative vomiting in the enrolled patients
The incidence of Postoperative delirium in ratepostoperative,24 hoursThe proportion of cases of postoperative delirium in the enrolled patients

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026